- Zomedica has partnered with Boehringer Ingelheim Animal Health Canada to expand PPID awareness, testing, and monitoring in horses across Canada using Zomedica’s TRUFORMA platform.
- Beginning this fall, participating equine practices will receive TRUFORMA analyzers at no cost, while eligible Boehringer customers will receive complimentary testing using TRUFORMA eACTH and insulin assays.
- The program aims to accelerate point-of-care diagnosis and treatment while expanding Zomedica’s installed base and introducing veterinarians to additional assays, including Cortisol and Progesterone.
- PPID affects about 20–25% of horses over 15. The collaboration is expected to improve access to specialized endocrine testing across Canada’s geographically dispersed equine veterinary practices.
Takeaways:
By placing TRUFORMA analyzers in equine clinics at no cost and offering free PPID testing cartridges to eligible Boehringer Ingelheim customers, the program makes it much easier and faster for vets to diagnose and monitor Cushing’s disease in horses without sending samples to a lab. This should increase testing rates (especially in Canada’s fall season when PPID screening peaks), improve early detection and treatment for older horses, and help Zomedica grow its installed base and recurring revenue as vets add more TRUFORMA assays like insulin, cortisol and progesterone.
Source: Access Newswire
